News

Novo Nordisk CEO warns of layoffs as Wegovy challenge heats up
Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could ...
Novo Nordisk’s Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues
Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded ...
Al Jazeera on MSN2d
Wegovy maker Novo Nordisk warns of layoffs as competition grows
Novo Nordisk’s outgoing CEO, Lars Fruergaard Jorgensen, has warned that layoffs at the Danish pharmaceutical giant could be ...
Wegovy maker Novo Nordisk warns on continued copycat-drug challenge as new CEO readied
Novo Nordisk cautioned on Wednesday that it expects continued competition this year from copycat versions of its Wegovy ...
Novo Nordisk's Weight Loss Challenge in Five Charts
Novo, valued at $650 billion in June last year, has shed over two-thirds of its value since. Its latest market cap is around ...
Devdiscourse2d
Novo Nordisk Faces Challenges as Copycat Competition Intensifies
Novo Nordisk experiences heightened competition from copycat versions of its Wegovy obesity drug, affecting its market share, ...
Wegovy maker Novo Nordisk to cut costs as weight-loss competition heats up
Novo Nordisk is to cut costs as the Wegovy-maker battles competition from rival Eli Lilly and copycat versions of its obesity ...
Cash pay is 'going to constitute a major part of the Wegovy business': Novo Nordisk CFO
Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...